RubioModi Meeting Puts US Energy Exports to India in Focus Amid Iran Tensions AI Economy Reshapes Labor Market BlueCollar Workers Could Emerge as Key Beneficiaries Telecoms CEO Warns Europe Faces Strategic Risk from US Satellite and AI Dominance Australia Urged to Simplify Regulatory Framework to Boost Capital Inflows Outgoing Watchdog Says Elon Musk Faces Legal Setback in OpenAI Lawsuit But Expected to Maintain Aggressive Approach Rise in Solar Panel Purchases Driven by Energy Cost Savings Company Director Invests in 2000 Panels Ducommun DCO Q1 2026 Earnings EPS Falls Short of Estimates Stock Edges Higher CLGN Q4 2025 Earnings EPS Misses Estimates as Biotech Continues PreRevenue Phase TaskUs Q1 2026 Earnings EPS Slightly Misses Estimates Stock Rises Saratoga Investment Corp 8125 Notes due 2027 SAY Q1 2026 Earnings Steep EPS Miss Weighs on Sentiment Despite Modest Price Recovery Wayfair Inc W Q1 2026 Earnings Marginal EPS Miss but Shares Gain on Profitability Focus DOYU Q4 2025 Earnings Massive EPS Surprise as Company Returns to Profitability MGP Ingredients Surges 27 Key Levels and Market Dynamics Quanterix QTRX Surges Over 15 Key Levels to Watch After Breakout MGP Ingredients Surges 27 Key Levels and Market Dynamics First Capital Inc FCAP Surges 47 as Momentum Builds Toward Key Resistance Neuropace Inc NPCE Surges 319 as Price Tests Key Resistance Zone Wall Street Sentiment Divided on Paramount Skydance Merger Prospects STWD Q1 2026 Earnings EPS Misses Estimates by Nearly 10 Guggenheim Taxable Municipal Bond Trust GBAB Sees Modest Uptick as RangeBound Trading Persists AMSF Q1 2026 Earnings EPS Misses Estimates as Stock Declines AREN Q1 2026 Earnings Misses Estimates on Significant EPS Shortfall PASG Q1 2026 Earnings SmallerthanExpected Loss Drives Positive Market Response NAGE Q1 2026 Earnings Modest EPS Beat Amid Limited Revenue Disclosure WLKP Q1 2026 Earnings EPS Misses Estimates Amid Challenging Chemical Market Fidelity D D Bancorp FDBC Q4 2025 Earnings Solid EPS of 137 Amid Quiet Market Reaction RNTX Q1 2026 Earnings EPS Beats Estimates as Preclinical Stage Biotech Tightens Spending